PREVENTION OF BIOFILMS IN MEDICAL DEVICES

预防医疗器械中的生物膜

• 批准号: 6694275
• 负责人: Saraswathi Mandapati
• 金额: $ 10万
• 依托单位: ALTUS PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2004-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6694275
• 关键词: SDS polyacrylamide gel electrophoresis; bacterial disease; bioassay; biofilm; biomedical equipment; biotechnology; blood transfusion; catheterization; crosslink; crystallization; disease /disorder prevention /control; drug delivery systems; enzyme activity; gel filtration chromatography; growth inhibitors; high performance liquid chromatography; implant; infection; infrared spectrometry; microorganism growth; orthopedics; peptidases; prosthesis; streptokinase; surface coating; transplantation

DESCRIPTION (provided by applicant): Design of new efficient drug delivery systems for proteins is one of the major themes of modern biotechnology and biopharmaceutical industry. We found that cross-linked enzyme crystals (CLECs) show remarkable stability at various pHs, on storage, against proteolysis and organic solvents. These properties make them ideal for treatment against biofilm formation on medical devices /implants such as urethral catheters, ureteric and prostatic stents, penile and testicular implants, artificial urinary sphincters, prostheses for hip and knee replacements, shunts for hydrocephalus, vascular grafts, heart valves, vascular access devices, voice prostheses, etc. In addition, the CLECS can be used for the prevention of blood clot formation, for example, in venous catheters. The CLEC agent will be used to coat the medical devices for the prevention of formation of bacterial biofilms on these devices as well as the prevention of blood clots. The biofilms form on the above medical devices by colonization of bacteria embedded in a matrix, which become resistant to commonly used antibiotics. In this Phase I study, we propose to develop two prototypes of CLECs of enzyme - Serratiopeptidase and Streptokinase for prevention of biofilms by Pseudomonas aeruginosa and Staphylococcus aureus microorganisms. The coating will prevent the adherence of these bacteria to medical devices. Currently, there are more than 850,000 case infections associated with aid devices annually in the United States. These may be associated with as many as 100,000 deaths per year. The CLECs of Serratiopeptidase and Streptokinase have enormous commercial potential over the currently available treatment for the prevention of contamination of medical devices by minimizing the need for replacement once they are implanted. The CLECs of Serratiopeptidase and Streptokinase will also be important in preventing biofilm-related infections which are resistant to commercially available antibiotics.

描述（由申请人提供）：针对蛋白质的新高效药物输送系统的设计是现代生物技术和生物制药行业的主要主题之一。我们发现，交联的酶晶体（CLEC）在各种pHS，存储，针对蛋白水解和有机溶剂上显示出显着的稳定性。这些特性使其成为针对医疗设备 /植入物（例如尿道导管，输尿管和前列腺架，阴茎和睾丸植入物，人造尿液括约肌，用于髋关节和膝关节的假体）等医疗设备 /植入物治疗的理想选择。用于预防血凝块形成，例如在静脉导管中。 CLEC剂将用于覆盖医疗设备，以预防这些设备上的细菌生物膜形成以及预防血液凝块。通过嵌入基质中的细菌定植在上述医疗设备上形成的生物膜，该细菌对常用抗生素具有抗性。在这一阶段I研究中，我们建议开发两种原型的酶 - 锯齿肽酶和链霉菌酶的原型，用于预防铜绿假单胞菌和金黄色葡萄球菌微生物的生物膜。涂层将防止这些细菌遵守医疗设备。目前，美国每年有850,000多个与AID设备相关的病例感染。这些可能与每年多达100,000人死亡有关。在当前可用的治疗方法上，塞拉二肽酶和链霉菌酶的CLEC具有巨大的商业潜力，以防止医疗设备的污染，一旦植入，它们的替换需求最小。 Serratiopeptidase和链霉菌酶的CLEC对于防止具有对市售抗生素具有抗性的生物膜相关感染也将很重要。